Breaking News Instant updates and real-time market news.

ESRX

Express Scripts

$73.67

0.4 (0.55%)

, CI

Cigna

$177.14

1.1 (0.62%)

08:00
05/17/18
05/17
08:00
05/17/18
08:00

Express Scripts shares should be bought right here, says Baird

Baird analyst Eric Coldwell revisited his thesis on Express Scripts (ESRX) following results, the President's drug pricing proposals, and the recent proxy filing. Despite the White House blueprint not containing any immediate proposals, he believes the shares are unloved and under-owned and are about the same price today as they were before the Cigna (CI) announcement. Coldwell believes the shares should be bought regardless of the Cigna outcome, citing Express Scripts' consistent fundamental performance and improving business outlook. Coldwell reiterated his Outperform rating and $92 price target on Express Scripts shares.

ESRX

Express Scripts

$73.67

0.4 (0.55%)

CI

Cigna

$177.14

1.1 (0.62%)

  • 21

    May

  • 12

    Jun

ESRX Express Scripts
$73.67

0.4 (0.55%)

04/17/18
LEER
04/17/18
NO CHANGE
LEER
Amazon, Trump news positive for drug supply chain, distributors, says Leerink
Leerink analyst Ana Gupte sees the dual pronged news flow on Amazon (AMZN) being unlikely to enter the Hospital drug supply chain, and President Trump poised to give a speech on drug pricing and supply chain reform on April 26 as HHS Secretary Alex Azar solicits ideas for pricing reform as positive for both the drug supply chain across PBMs and drug distributors and biopharma manufacturers that have been roiled by fears of margin compression on both these threats. Within her coverage, the analyst views this as positive for UnitedHealth (UNH) with its Optum Rx PBM, Cigna (CI) with its deal to acquire Express Scripts (ESRX), and Aetna (AET) which has inked a deal with CVS (CVS) in part through equity, as well as Anthem (ANTM) with IngenioRx and Humana (HUM) with or without its potential Walmart (WMT) deal that has a sizable mail order operation.
05/01/18
PIPR
05/01/18
NO CHANGE
PIPR
Overweight
Piper says Regeneron deal with Express Scripts for Praluent 'looks meaningful'
Piper Jaffray analyst Christopher Raymond said Regeneron's (REGN) agreement with Express Scripts (ESRX) to improve Praluent access and make it the exclusive PCSK9 on the latter's preferred formulary may "set a somewhat dubious precedent," but he still sees it as a smart move that can reinvigorate Praluent growth. The analyst, who would expect similar agreements with other payers and PBMs are already in the works, keeps an Overweight rating on Regeneron shares.
05/03/18
LEER
05/03/18
NO CHANGE
Target $80
LEER
Market Perform
Express Scripts price target lowered to $80 from $90 at Leerink
Leerink analyst David Larsen lowered his price target for Express Scripts to $80 from $90 after the company reported mixed Q1 results and mostly reaffirmed prior 2018 guidance. The analyst reiterates a Market Perform rating on the shares.
05/03/18
PIPR
05/03/18
NO CHANGE
Target $450
PIPR
Overweight
Piper positive on Regeneron's 2018 set-up given Eylea strength, Praluent upside
Piper Jaffray analyst Christopher Raymond said he like the setup for Regeneron (REGN) for the rest of the year following the company's Q1 report. He thinks Eylea's strength can continue, Dupixent demand trends will remain healthy and that its recently announced Express Scripts (ESRX) deal can potentially reinvigorate Praluent and offers second half upside. Raymond maintains his Overweight rating on Regeneron, though he lowered his price target on the shares to $450 from $500 as he reduced his multiple given recent volatility in the space.
CI Cigna
$177.14

1.1 (0.62%)

03/13/18
BERN
03/13/18
INITIATION
Target $194
BERN
Market Perform
Cigna initiated with a Market Perform at Bernstein
Bernstein analyst Lance Wilkes initiated Cigna (CI) with a Market Perform rating and $195 price target following Cigna's announcement that it will buy Express Scripts (ESRX) for $67B. Wilkes views the deal as a bet that change comes more slowly to healthcare, and that financial returns from this deal will fund future strategic acquisitions for Cigna. In a research note to investors, Wilkes said he believes disruption is coming more quickly, in PBM and pharmacy and in the shift to value, and is "skeptical" of this move by Cigna. The analyst expects earnings growth to slow for Cigna driven by its employer focus, lack of scale and already best in class margins, and added that he has a "negative" outlook for Express Scripts, expecting declining gross margins as they lose Anthem (ANTM) and client pricing pressure as focus increases on drug costs.
03/15/18
DBAB
03/15/18
NO CHANGE
Target $236
DBAB
Buy
Cigna shares look oversold with or without deal, says Deutsche Bank
Cigna (CI) shares are down 26% from the January $226 high and 14% since the Express Scripts (ESRX) deal was announced on March 8, Deutsche Bank analyst Chris Rigg tells investors in a research note. The analyst estimates pro forma 2021 earnings per share of $21.18 for Cigna and Express Scripts. As such, he sees "ample conservatism" in management's 2021 EPS target range of $20-$21. With or without the deal, Cigna shares look oversold, Rigg contends. He keeps a Buy rating on Cigna with a $236 price target.
04/02/18
LEER
04/02/18
NO CHANGE
LEER
Possible Humana/Walmart deal transformational for U.S. seniors market, says Leerink
Leerink analyst Ana Gupte sees the possible Humana (HUM)-Walmart (WMT) deal as transformational for the U.S. Seniors market and estimates the deal value at close to $50B. The analyst also believes the deal helps Humana compete more effectively with UnitedHealth (UNH)/Optum and Aetna (AET)-CVS (CVS), while Walmart can also compete with Amazon (AMZN) that is eroding sales and likely eyeing an entry into the Prescription Rx market. Gupte expects the anti-trust scrutiny of three deals Aetna-CVS, Cigna (CI)-Express Scripts (ESRX) and Humana-Walmart by the DOJ will be more challenged under simultaneous review by the DOJ, though Walmart and Humana have the least anti-competitive issues. Humana-Walmart could catalyze a counter-offer for Cigna from Walgreens Boots Alliance (WBA) or even Amazon, or re-invigorate Walgreens-AmerisourceBergen (ABC) talks, she contends.

TODAY'S FREE FLY STORIES

TPX

Tempur Sealy

$55.12

1.16 (2.15%)

, SNBR

Sleep Number

$37.25

0.44 (1.20%)

07:03
09/19/18
09/19
07:03
09/19/18
07:03
Recommendations
Tempur Sealy, Sleep Number, Purple, Taken private analyst commentary  »

Antidumping petition…

TPX

Tempur Sealy

$55.12

1.16 (2.15%)

SNBR

Sleep Number

$37.25

0.44 (1.20%)

PRPL

Purple

$5.49

0.08 (1.48%)

MFRM

Taken private

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$38.49

2.07 (5.68%)

07:03
09/19/18
09/19
07:03
09/19/18
07:03
Hot Stocks
Unum Group selects Clearwater for investment accounting system solution »

Clearwater Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$14.89

0.24 (1.64%)

07:02
09/19/18
09/19
07:02
09/19/18
07:02
Hot Stocks
Canadian Solar to supply 164 MW of modules to project in Spain »

Canadian Solar has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCRA

Vocera

$33.51

0.01 (0.03%)

07:02
09/19/18
09/19
07:02
09/19/18
07:02
Initiation
Vocera initiated  »

Vocera initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

PAH

Platform Specialty Products

$12.80

0.01 (0.08%)

06:58
09/19/18
09/19
06:58
09/19/18
06:58
Downgrade
Platform Specialty Products rating change  »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$163.70

6.97 (4.45%)

, CNI

Canadian National

$87.47

-0.195 (-0.22%)

06:56
09/19/18
09/19
06:56
09/19/18
06:56
Recommendations
Union Pacific, Canadian National, Canadian Pacific, CSX analyst commentary  »

Union Pacific shares…

UNP

Union Pacific

$163.70

6.97 (4.45%)

CNI

Canadian National

$87.47

-0.195 (-0.22%)

CP

Canadian Pacific

$206.96

1.38 (0.67%)

CSX

CSX

$74.12

0.77 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

  • 16

    Oct

  • 18

    Oct

  • 06

    Nov

ROIC

Retail Opportunity

$18.87

-0.215 (-1.13%)

06:55
09/19/18
09/19
06:55
09/19/18
06:55
Initiation
Retail Opportunity initiated  »

Retail Opportunity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AFIN

American Finance Trust

$17.52

0.53 (3.12%)

06:50
09/19/18
09/19
06:50
09/19/18
06:50
Initiation
American Finance Trust initiated  »

American Finance Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$7.55

0.97 (14.74%)

, FSLR

First Solar

$49.56

1.81 (3.79%)

06:50
09/19/18
09/19
06:50
09/19/18
06:50
Recommendations
SunPower, First Solar analyst commentary  »

JPMorgan 'warming…

SPWR

SunPower

$7.55

0.97 (14.74%)

FSLR

First Solar

$49.56

1.81 (3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$43.09

-0.41 (-0.94%)

06:50
09/19/18
09/19
06:50
09/19/18
06:50
Hot Stocks
AutoNation extends CEO Mike Jackson's contract »

AutoNation announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ZYME

Zymeworks

$14.40

0.035 (0.24%)

06:48
09/19/18
09/19
06:48
09/19/18
06:48
Hot Stocks
Zymeworks names Anthony Polverino Chief Scientific Officer »

Zymeworks has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$42.00

-0.05 (-0.12%)

06:45
09/19/18
09/19
06:45
09/19/18
06:45
Recommendations
SolarEdge analyst commentary  »

SolarEdge tariff risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
09/19/18
09/19
06:45
09/19/18
06:45
General news
Breaking General news story  »

Week of 9/14 MBA Mortgage…

IBKC

Iberiabank

$83.70

-0.5 (-0.59%)

06:44
09/19/18
09/19
06:44
09/19/18
06:44
Conference/Events
Iberiabank management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

KBR

KBR

$20.19

0.37 (1.87%)

06:44
09/19/18
09/19
06:44
09/19/18
06:44
Downgrade
KBR rating change  »

KBR downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$732.74

-14.79 (-1.98%)

06:41
09/19/18
09/19
06:41
09/19/18
06:41
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BAYRY

Bayer

$0.00

(0.00%)

06:40
09/19/18
09/19
06:40
09/19/18
06:40
Periodicals
Bayer wants to overturn $289M in damages ordered in weed killer case, WSJ says »

Bayer is looking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 29

    Oct

LYB

LyondellBasell

$102.16

-1.3 (-1.26%)

06:38
09/19/18
09/19
06:38
09/19/18
06:38
Downgrade
LyondellBasell rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

06:36
09/19/18
09/19
06:36
09/19/18
06:36
Periodicals
CEO says blockchain 'not ready' to fully support global supply chain, CNBC says »

Tradeshift CEO and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCRX

Pacira

$47.85

1.6 (3.46%)

06:36
09/19/18
09/19
06:36
09/19/18
06:36
Recommendations
Pacira analyst commentary  »

Pacira price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

$114.86

-0.6 (-0.52%)

, BIDU

Baidu

$216.99

-0.58 (-0.27%)

06:34
09/19/18
09/19
06:34
09/19/18
06:34
Hot Stocks
Wabco and Baidu to collaborate on commercial vehicle autonomous driving »

Wabco (WBC) signed a…

WBC

Wabco

$114.86

-0.6 (-0.52%)

BIDU

Baidu

$216.99

-0.58 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 06

    Nov

NVCR

Novocure

$49.00

2.625 (5.66%)

06:34
09/19/18
09/19
06:34
09/19/18
06:34
Recommendations
Novocure analyst commentary  »

Novocure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBRL

Cracker Barrel

$143.77

-6.93 (-4.60%)

06:30
09/19/18
09/19
06:30
09/19/18
06:30
Recommendations
Cracker Barrel analyst commentary  »

Cracker Barrel needs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BABA

Alibaba

$156.64

-2.12 (-1.34%)

06:30
09/19/18
09/19
06:30
09/19/18
06:30
Periodicals
China's Alibaba to set up dedicated chip subsidiary, Reuters reports »

Alibaba is planning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

ABUS

Arbutus Biopharma

$9.55

0.25 (2.69%)

06:30
09/19/18
09/19
06:30
09/19/18
06:30
Conference/Events
Arbutus Biopharma management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.